title: Perspectives: towards a peptide-based vaccine against hepatitis C virus.
abstract: Hepatitis C virus (HCV) is a widespread infectious disease in humans with the negative implication of becoming chronic in most persons. Patients infected with HCV are at risk of liver cirrhosis or hepatocellular carcinoma at later stages. In contrast to hepatitis A and hepatitis B, there is no immunization yet available, neither prophylactic nor therapeutic. Thus, there is an urgent need to develop a safe, protective vaccine against this fatal disease. Developing countries are even more at risk for HCV. There are currently a number of scientific approaches aimed towards solving this problem. Taking both risks and costs of immunization into consideration, a peptide-based vaccine may be a reasonable prophylactic protection. Also, it might be of therapeutic use in already infected patients by increasing a specific CTL response against HCV. In our lab, we are focusing on immunopotentiating reconstituted influenza virosomes (IRIVs) as carriers for immunogenic HLA-A2-restricted core epitopes to induce peptide-specific cytotoxic T lymphocytes (CTLs). The IRIVs are similar to liposomes, but in addition contain influenza-derived hemagglutinin and neuraminidase on their outer surface which makes them fusogenic, thus, permitting antigen delivery to host cells. So far, virosomes have been successfully used for vaccine development and as a result a virosomal vaccine against both influenza virus (Inflexal) BERNA) and hepatitis A virus (HAV) (Epaxal) BERNA) already exist on the market. This paper focuses on the importance of development of a successful vaccine against HCV and, more specifically, we discuss the use, advantages and disadvantages of a peptide-based vaccine. A brief report of our latest findings will be included.
authors.affiliation: Clinic of Rheumatology and Clinical Immunology/Allergology, University Hospital, Inselspital Bern, 3010, Bern, Switzerland.
authors.forename: I P
authors.initials: IP
authors.lastname: Hunziker
authors.forename: R
authors.initials: R
authors.lastname: Zurbriggen
authors.forename: R
authors.initials: R
authors.lastname: Glueck
authors.forename: O B
authors.initials: OB
authors.lastname: Engler
authors.forename: J
authors.initials: J
authors.lastname: Reichen
authors.forename: W J
authors.initials: WJ
authors.lastname: Dai
authors.forename: W J
authors.initials: WJ
authors.lastname: Pichler
authors.forename: A
authors.initials: A
authors.lastname: Cerny
mesh_terms: D015789:HLA-A2 Antigen / Q000276:immunology; D016174:Hepacivirus / Q000276:immunology*; D006526:Hepatitis C / Q000276:immunology* / Q000517:prevention & control; D006801:Humans; D009975:Orthomyxoviridae / Q000737:chemistry / Q000276:immunology; D010455:Peptides / Q000737:chemistry / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D022223:Vaccines, Subunit / Q000276:immunology* / Q000627:therapeutic use; D022721:Vaccines, Virosome / Q000737:chemistry / Q000276:immunology* / Q000627:therapeutic use; D014761:Viral Hepatitis Vaccines / Q000276:immunology* / Q000627:therapeutic use
chemical_list: D015789:HLA-A2 Antigen; D010455:Peptides; D022223:Vaccines, Subunit; D022721:Vaccines, Virosome; D014761:Viral Hepatitis Vaccines